Back to homepage

Tag "COVID-19"

Combating the opioid epidemic in the United States

Authors: A Simon Pickard, Todd A Lee

This editorial discusses the series of papers that feature initiatives to mitigate the opioid epidemic in the United States, and challenges encountered during the Covid-19 pandemic.

More

Vitamins, supplements and COVID-19: a review of currently available evidence

Authors: Lauren Speakman, Sarah Michienzi, Melissa Badowski

The purpose of this review was to analyse clinical trials regarding vitamins and supplements for the treatment of COVID-19 infections.

More

Response to ‘Presentation and pathophysiology of neuro-COVID’

Authors: Daniele Orsucci, Marco Vista

Letter to the Editor in response to Finsterer J, Scorza FA, Scorza CA. Presentation and pathophysiology of neuro-COVID. Drugs Context. 2021;10:2021-6-5

More

Presentation and pathophysiology of neuro-COVID

Authors: Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.

More

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Authors: Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1

More